Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metabolic States of the Body: Fasting and Starvation01:24

Metabolic States of the Body: Fasting and Starvation

During the initial hours of fasting, the body uses up its glycogen stores as an energy source. Once these glycogen reserves are depleted, the body begins breaking down stored triglycerides and structural proteins. During this stage, glycerol becomes a key substrate for gluconeogenesis, while free fatty acids undergo beta-oxidation to provide energy for tissues, such as skeletal muscle. In the fasting state, the body spares protein breakdown as much as possible to conserve muscle and structural...
Metabolic States of the Body: The Postabsorptive State01:18

Metabolic States of the Body: The Postabsorptive State

The postabsorptive state usually starts about four hours after a meal and lasts until the next meal is eaten. During this time, the digestive system stops absorbing nutrients, and the body uses stored energy reserves to maintain stable blood glucose levels.
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hyperosmolar Hyperglycemic State01:21

Hyperosmolar Hyperglycemic State

Hyperosmolar Hyperglycemic State, or HHS, is a serious and life-threatening complication of type 2 diabetes mellitus. It is characterized by three main features: severe hyperglycemia, profound dehydration, and elevated serum osmolality, all occurring without significant ketoacidosis.HHS typically develops in older adults or individuals with limited access to fluids. This may result from illness, cognitive impairment, or medications such as diuretics or corticosteroids. These factors reduce...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort.

Cephalalgia : an international journal of headache·2026
Same author

Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.

Neurology and therapy·2026
Same author

Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.

Neurology·2026
Same author

Responders and super-responders to atogepant after 24 weeks of treatment in migraine: real-world evidence from the GIANT-2 study.

The journal of headache and pain·2026
Same author

Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.

Neurology·2026
Same author

Introducing the four dimensions 4D migraine scale: A composite score proposal evaluating migraine severity and treatment efficacy.

Cephalalgia : an international journal of headache·2025
Same journal

Analysis of the Effectiveness of Injection-Based Minimally Invasive Treatment for Piriformis Syndrome: Clinical Outcomes and Anatomical Correlates.

Current pain and headache reports·2026
Same journal

A Systematic Review and Meta-Analysis of Randomized Controlled Trials of Epidural Regenerative Medicine Therapies in Managing Spinal Pain.

Current pain and headache reports·2026
Same journal

Artificial Intelligence in Neuropathic Pain: From Mechanisms to Neuromodulation and Regenerative Strategies.

Current pain and headache reports·2026
Same journal

Proposed Conditions for Pain Reprocessing Therapy Readiness: Beyond Phenotyping Neuroplastic Pain.

Current pain and headache reports·2026
Same journal

Treatment of Headache in Children and Adolescents with POTS.

Current pain and headache reports·2026
Same journal

Pediatric Headache in the Age of Social Media: A Topical Review.

Current pain and headache reports·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Fasting headache.

Paola Torelli1, Gian Camillo Manzoni

  • 1Headache Center, Department of Neuroscience, University of Parma, Italy. paolatorelli@libero.it

Current Pain and Headache Reports
|May 22, 2010
PubMed
Summary
This summary is machine-generated.

Fasting headache affects 4.1% of the general population, often occurring after 16 hours without food. This mild to moderate headache resolves after eating but is more common in those who regularly experience headaches.

More Related Videos

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
08:30

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

Related Experiment Videos

Last Updated: Jun 12, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
08:30

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

Area of Science:

  • Neurology
  • Internal Medicine

Background:

  • Headache is a prevalent neurological disorder.
  • Fasting headache (Group 10, International Classification of Headache Disorders) is attributed to disorders of homeostasis.
  • Previous research indicates a significant prevalence of fasting headache in the general population.

Purpose of the Study:

  • To investigate the prevalence and characteristics of fasting headache.
  • To identify risk factors associated with fasting headache.

Main Methods:

  • A population-based study was conducted in Denmark.
  • Data on headache prevalence and characteristics were collected.

Main Results:

  • The lifetime prevalence of fasting headache was found to be 4.1% in the Danish general population.
  • Fasting headache typically presents as diffuse or frontal, non-pulsating pain of mild to moderate intensity.
  • Headache onset occurs after at least 16 hours of fasting, resolving within 72 hours of refeeding.
  • The duration of fasting directly correlates with the likelihood of developing fasting headache.
  • Individuals with a history of headache are at a higher risk for fasting headache.

Conclusions:

  • Fasting headache is a common condition with a defined prevalence in the general population.
  • Factors such as hypoglycemia and caffeine withdrawal are suspected contributors, warranting further investigation.
  • Understanding the pathophysiology of fasting headache is crucial for effective management and prevention strategies.